The ESMO Gastrointestinal Cancers Congress (ESMO-GI 2024), to be held in Munich, Germany, from June 26 to 29, 2024, will also be accessible online via a dedicated virtual platform, allowing global participation. ESMO-GI 2024 promises to be a significant gathering for gastrointestinal (GI) oncology professionals. It will showcase impactful new research and offer extensive educational and networking opportunities.
ESMO-GI 2024: Scientific Co-Chairs and Organizers
Three distinguished Co-Chairs manage the scientific leadership of ESMO GI 2024:
- Michel Ducreux (Gustave Roussy, Villejuif, France)
- Teresa Macarulla (University Hospital of Vall d’Hebron, Barcelona, Spain)
- Eric Van Cutsem (University Hospitals Leuven, Belgium)
ESMO-GI 2024: Scientific and Educational Sessions
ESMO-GI 2024 will feature a comprehensive scientific program that includes keynote lectures, educational sessions, multidisciplinary tumor board sessions, special symposia, and a poster exhibition.
These sessions aim to update oncology healthcare professionals on recent advancements in managing GI malignancies, insights into molecular prevention, diagnosis, and precision therapy, and expert knowledge on controversial areas in GI oncology.
Key Objectives of ESMO-GI 2024:
- Update attendees on state-of-the-art management of GI cancers.
- Present the latest insights in molecular prevention, diagnosis, and precision therapy.
- Provide in-depth knowledge on controversial areas in GI oncology.
ESMO-GI 2024: Satellite Symposia
Several industry-sponsored satellite symposia will focus on cutting-edge topics such as treatment goals, clinical endpoints, real-world evidence, and novel therapies in GI cancer care. Some notable sessions include:
- Treatment Goals, Clinical Endpoints, RCTs and RWEs: Navigating decision-making in first-line hepatocellular carcinoma. The symposium is fully funded by Eisai.
- Improving Patient Care: This session will be conducted by Sylvie Lorenzen (Rechts der Isar Hospital of the Technical University of Munich).
Faculty members Samuel Klempner (Massachusetts General Hospital Cancer Center, Boston, USA) and Arndt Vogel (Hannover Medical School, Hannover, Germany) will focus on advanced gastroesophageal and biliary cancer.
- Real World Evidence: Advancing later-line GI cancer therapy:
Speakers will be Luís Castelo-Branco (IOSI Oncologist Institute of Southern Switzerland), Richard Kim (Moffitt Cancer Center Magnolia Campus, Florida), and Gerald Prager (Medical University of Vienna and Comprehensive Cancer Center Vienna, Austria).
- Challenges with BRAFV600E mutant mCRC: It will be presented by Julien Taieb (Université Paris Descartes, Paris, France).
Chiara Cremolini (University of Pisa, Italy) and Dominik Modest (Charité – Universitätsmedizin, Berlin, Germany) will also discuss this.
The session will discuss how to navigate the complex clinical data of patients with BRAFV600E mutant mCRC. Further discussion will be based on learning from experience and utilizing real-world evidence-based data.
- Perspectives on the Current and Future Management of mCRC: Consensus and Controversies:
Speakers will be Julien Taieb (Université Paris Descartes, Paris, France), Jenny Seligmann (University of Leeds, UK), Dominik Modest (Charité – Universitätsmedizin Berlin, Germany), and Sara Lonardi (Veneto Institute of Oncology (IOV) – IRCCS, Italy).
- Precision Oncology: Latest Developments in GI Cancer Care:
Speakers will be Marker Moehler (Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Germany), Hans Prehen (University Hospital Antwerp, Belgium) and Magali Svrcek (Sorbonne Université, France).
The session will be about biomarker-guided treatment and the role of combination therapies. Further discussion will focus on targeted therapies, current biomarker testing practices, and future considerations for G/GEJ cancers.
- Advances in Upper GI Immunotherapy: What’s New on the Horizon?
This session will be chaired by Sylvie Lorenzen (Technical University Munich, Germany).
Speakers will be Filippo Pietrantonio (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Jean-Philippe Metges (Cancer and Hematology Institute, Brest University Hospital, Brest, France), Matteo Fassan (Padua University, Padua, Italy) and Maria Alsina (Navarra Hospital Complex – Navarra Hospital, Navarra, Spain).
ESMO-GI 2024: Research Highlights
- Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial. Speaker: Mehraneh Dorna Jafari (Weill Cornell Medicine, New York, USA).
- CD40 agonist mitazalimab combined with mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Primary analysis of the OPTIMIZE-1 phase Ib/II study. Speaker: Teresa Macarulla Mercade (Vall d’Hebron University Hospital, Barcelona, Spain).
- Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201. Speaker: Kristen K. Ciombor (Vanderbilt University Medical Center, Nashville, USA).
- A PBO-controlled study comparing doses and efficacy of lentinula edodes mycelia for chemotherapy-induced peripheral neuropathy in colorectal cancer: The LEMON trial. Speaker: Hironaga Satake (Kochi Medical School, Nankoku, Japan).
- Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in pts (pts) with solid tumors and gastric/gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase I study. Speaker: Jia Jenny Liu (The Kinghorn Cancer Centre,Darlinghurst, Australia).
- Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306. Speaker: Eric Raymond (Saint-Joseph Hospital, Paris, France).
ESMO-GI 2024 is a global platform for the GI oncology community to present and discuss cutting-edge research on improving patient care. The event provides an opportunity to gain insights from leading experts, participate in high-quality educational sessions, and network with peers and industry leaders.
Attendees can learn about advances and innovations in the treatment of GI cancer, ensuring that new practice-changing discoveries can be applied to benefit patients worldwide.
ESMO-GI 2024 Event Sponsors:
Platinum sponsors: AstraZeneca, Bristol Myers Squibb, GSK, Merck, and Servier.
Gold sponsors: Amgen, Astellas Pharma, Bayer, Beigene, Daiichi Sankyo, Eisai, MSD, Pierre Fabre, Roche, and Taiho Oncology Europe.
Silver sponsor: AbbVie Inc.
Bronze sponsors: Agenus, Fresenius Kabi, Incyte, Jazz Pharmaceuticals, Pfizer, and Takeda Pharmaceuticals.
